INOVIO to Present at Upcoming Scientific and Investor Conferences

Rhea-AI Summary

INOVIO, a biotechnology company developing DNA medicines, has announced its participation in several major scientific and investor conferences in May 2025. The company will present at the Citizens JMP Life Sciences Conference in New York through a fireside chat on May 8.

Notably, INOVIO will showcase new data about their lead candidate INO-3107 at multiple venues. Key presentations include:

• European Laryngological Society Annual Congress: Results showing 81% surgery reduction in adults with recurrent respiratory papillomatosis
• American Society of Gene and Cell Therapy: Treatment outcomes for recurrent respiratory papillomatosis
• American Broncho-Esophagological Association: Long-term clinical effects of INO-3107 in treating HPV 6 & 11-caused respiratory papillomatosis

Abstracts will be available on INOVIO's website after presentations, with the JMP conference webcast replay accessible for 90 days.

Positive

• INO-3107 shows strong clinical efficacy with 81% surgery reduction in adults with recurrent respiratory papillomatosis
• Multiple scientific presentations at major medical conferences indicating strong clinical data pipeline
• Successful treatment outcomes reported regardless of papilloma microenvironment and molecular subtype, suggesting broad applicability

Negative

• None.

PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.

Citizens JMP Life Sciences Conference (NY)
Date: May 8
Time: 11:30am EDT
Format: Fireside Chat
(audio webcast available here: https://wsw.com/webcast/jmp65/ino/1544620)

European Laryngological Society Annual Congress (Warsaw, PL)
Date: May 9
Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1

American Society of Gene and Cell Therapy (New Orleans, LA)
Date: May 13
Poster Abstract Session: Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype

ABEA at COSM (New Orleans, LA)
Date: May 15
Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11

Available abstracts will be shared on INOVIO's website following presentations. An audio replay of the Citizens JMP webcast will be available for 90 days after the event.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-and-investor-conferences-302442322.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) present at the Citizens JMP Life Sciences Conference 2025?

INOVIO will present a fireside chat at the Citizens JMP Life Sciences Conference in New York on May 8, 2025, at 11:30am EDT. The audio webcast will be available online and accessible for 90 days after the event.

What are the key findings of INOVIO's INO-3107 treatment for respiratory papillomatosis?

INOVIO's INO-3107 DNA immunotherapy showed an 81% surgery reduction rate in adults with recurrent respiratory papillomatosis during the first year of treatment, targeting HPV 6 & 11.

Which scientific conferences will INOVIO present at in May 2025?

INOVIO will present at four conferences: Citizens JMP Life Sciences Conference (NY, May 8), European Laryngological Society Annual Congress (Warsaw, May 9), American Society of Gene and Cell Therapy (New Orleans, May 13), and ABEA at COSM (New Orleans, May 15).

What is INOVIO's INO-3107 long-term clinical data presentation schedule?

INOVIO will present INO-3107's long-term clinical effect data at the American Broncho-Esophagological Association (ABEA) program during COSM in New Orleans on May 15, 2025.

How effective is INOVIO's INO-3107 across different papilloma subtypes?

According to the presentation abstract, INO-3107 successfully treats Recurrent Respiratory Papillomatosis regardless of papilloma microenvironment and molecular subtype.